Targeted liposomal drug delivery systems for the treatment of B cell malignancies

References

• Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649–59
   PubMed Web of Science ®Google Scholar
• Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer 1989;63:604–12
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu F, Chan J, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2007;83:761–9
   PubMed Web of Science ®Google Scholar
• Sahoo S, Parveen S, Panda J. The present and future of nanotechnology in human health care. Nanomed: Nanotechnol Biol Med 2007;3:20–31
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60:1615–26
   PubMed Web of Science ®Google Scholar
• Bharali DJ, Mousa SA. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther 2010;128:324–35
   PubMed Web of Science ®Google Scholar
• Zamboni WC. Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 2005;11:8230–4
   PubMed Web of Science ®Google Scholar
• Molema G. Drug targeting: basic concepts and novel advances. In: Molema G, Meijer DKF, eds. Drug targeting: organ-specific strategies. Vol. 12. Weinheim: Wiley-VCH Verlag GmbH; 2001:1--22
   Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771–82
   PubMed Web of Science ®Google Scholar
• Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomed 2007;2:567–83
   PubMed Web of Science ®Google Scholar
• Omura S, Tanaka H, Oiwa R, et al. New antitumor antibiotics, OS-4742 A 1, A 2, B 1 and B 2 produced by a strain of Streptomyces. J Antibiotics 1977;30:908–16
   PubMed Web of Science ®Google Scholar
• Rinehart J, Lewis RP, Balcerzak SP. Adriamycin cardiotoxicity in man. Ann Intern Med 1974;81:475--8
   PubMed Web of Science ®Google Scholar
• Thierry AR, Vige D, Coughlin SS, et al. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J 1993;7:572–9
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002;54:631–51
   PubMed Web of Science ®Google Scholar
• Harris N, Jaffe E, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000;36:69–86
   PubMedGoogle Scholar
• Swerdllow S, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press; 2008
   Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–11
   PubMed Web of Science ®Google Scholar
• Society. Leukemia and lymphoma. White Plains (NY): Facts Spring; 2013
   Google Scholar
• Leonard B. Leukemia: a research report. Darby (PA): Diane Pub Co; 1998
   Google Scholar
• Mackey JR, Kerbel RS, Gelmon KA, et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev 2012;38:673–88
   PubMed Web of Science ®Google Scholar
• Soultati A, Mountzios G, Avgerinou C, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev 2012;38:473–83
   PubMed Web of Science ®Google Scholar
• Marchese VG, Morris GS, Gilchrist L, et al. Screening for chemotherapy adverse late effects. Topics Geriat Rehabil 2011;27:234–43
   Web of Science ®Google Scholar
• Gupta S, Kanodia AK. Biological response modifiers in cancer therapy. Natl Med J India 2002;15:202–7
   PubMed Web of Science ®Google Scholar
• Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 2008;359:613–26
   PubMed Web of Science ®Google Scholar
• Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154--69
   PubMed Web of Science ®Google Scholar
• Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235–44
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nano 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Dijoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res 2006;12:242–9
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunol 2002;3:991–8
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190–4
   PubMed Web of Science ®Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature Rev Cancer 2002;2:750–63
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv. J Control Rel 2008;126:50–8
   PubMed Web of Science ®Google Scholar
• Loomis K, Smith B, Feng Y, et al. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Experiment Molec Pathol 2010;88:238–49
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res 2004;10:2530--7
   PubMed Web of Science ®Google Scholar
• Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Rel 2006;115:251–8
   PubMed Web of Science ®Google Scholar
• Ichihara M, Shimizu T, Imoto A, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 2011;3:1–11
   Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Rel 2010;148:135–46
   PubMed Web of Science ®Google Scholar
• Hirsjärvi S, Passirani C, Benoit JP. Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 2011;8:188–96
   PubMedGoogle Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387–92
   PubMed Web of Science ®Google Scholar
• Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008;3:703–17
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457–64
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812–18
   PubMed Web of Science ®Google Scholar
• Maeda H, Takeshita J, Kanamaru R. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res 1979;14:81–7
   PubMedGoogle Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001;46:169–85
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Rel 2000;65:271–84
   PubMed Web of Science ®Google Scholar
• Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010;62:90–9
   PubMed Web of Science ®Google Scholar
• Düzgüneş N, Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 1999;40:3–18
   PubMed Web of Science ®Google Scholar
• Xiao K, Luo J, Li Y, et al. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Rel 2011;155:272--81
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529–37
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320–30
   PubMed Web of Science ®Google Scholar
• de Menezes DEL, Kirchmeier MJ, Gagne JF, et al. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J Liposome Res 1999;9:199–228
   Web of Science ®Google Scholar
• Ishida T, Kirchmeier MJ, Moase EH, et al. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 2001;1515:144–58
   PubMed Web of Science ®Google Scholar
• Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab’ fragments. Clin Cancer Res 2004;10:1100–11
   PubMed Web of Science ®Google Scholar
• Allen TM, Mumbengegwi DR, Charrois GJR. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 2005;11:3567--73
   PubMed Web of Science ®Google Scholar
• Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999;43:1–7
   PubMed Web of Science ®Google Scholar
• Bhattacharjee H, Balabathula P, Wood GC. Targeted nanoparticulate drug-delivery systems for treatment of solid tumors: a review. Therapeutic Deliv 2010;1:713–34
   PubMedGoogle Scholar
• Rodriguez M, Pytlik R, Kozak T, et al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma. Cancer 2009;115:3475–82
   PubMed Web of Science ®Google Scholar
• Sarris AH, Cabanillas F, Logan PM, et al. Compositions and methods for treating lymphoma. Google Patents; 2004
   Google Scholar
• Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin’s lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000;11:69–72
   PubMed Web of Science ®Google Scholar
• Booser DJ, Esteva FJ, Rivera E, et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol 2002;50:6–8
   PubMed Web of Science ®Google Scholar
• Wetzler M, Thomas DA, Wang ES, et al. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leukemia 2013;13:430–4
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 2013;65:36–48
   PubMed Web of Science ®Google Scholar
• Chang H, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed 2012;7:49–60
   PubMed Web of Science ®Google Scholar
• Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta – Biomembranes 1993;1151:201–15
   PubMed Web of Science ®Google Scholar
• Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. Biochim Biophys Acta (BBA) –Biomembranes 2001;1513:207–16
   PubMed Web of Science ®Google Scholar
• Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352–5
   PubMed Web of Science ®Google Scholar
• Benita S. Microencapsulation: methods and industrial applications. Informa Health 2006;158:123--48
   Google Scholar
• Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta (BBA)-Biomembranes 2004;1663:167–77
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes DE, Pilarski LM, Belch AR, Allen TM. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000;1466:205–20
   PubMed Web of Science ®Google Scholar
• Mayer LD, Nayar R, Thies RL, et al. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 1994;33:17–24
   Web of Science ®Google Scholar
• Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cellular Molecr Biol Lett 2002;7:217–19
   PubMed Web of Science ®Google Scholar
• Zhang J, Tang Y, Qian B, Sheng H. Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8. J Huazhong Univ Sci Technol – Med Sci 2010;30:240–7
   PubMed Web of Science ®Google Scholar
• Kirchmeier MJ, Ishida T, Chevrette J, Allen TM. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Liposome Res 2001;11:15–29
   PubMed Web of Science ®Google Scholar
• Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009;71:431–44
   PubMed Web of Science ®Google Scholar
• Powell LD, Varki A. The oligosaccharide binding specificities of CD22β, a sialic acid-specific lectin of B cells. J Biol Chem 1994;269:10628–36
   PubMed Web of Science ®Google Scholar
• Chen WC, Completo GC, Sigal DS, et al. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 2010;115:4778–86
   PubMed Web of Science ®Google Scholar
• O’Donnell RT, Martin SM, Ma Y, et al. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD). Investigat New Drugs 2010;28:260–7
   PubMed Web of Science ®Google Scholar
• Sakakibara T, Chen FA, Kida H, et al. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996;56:3743–6
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Martin SM, Ma Y, et al. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin’s lymphoma xenograft mouse model. Clin Cancer Res 2010;16:2760--8
   PubMed Web of Science ®Google Scholar
• Puri A, Kramer-Marek G, Campbell-Massa R, et al. HER2-specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents. J Liposome Res 2008;18:293–307
   PubMed Web of Science ®Google Scholar
• Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res 2008;68:6300–5
   PubMed Web of Science ®Google Scholar
• Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Rel 2004;94:155–61
   PubMed Web of Science ®Google Scholar
• Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007;104:13408–13
   PubMed Web of Science ®Google Scholar
• Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008;283:2784–92
   PubMed Web of Science ®Google Scholar
• Hertlein E, Triantafillou G, Sass EJ, et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010;116:2554–8
   PubMed Web of Science ®Google Scholar
• Mao Y, Triantafillou G, Hertlein E, et al. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res 2013;19:347–56
   PubMed Web of Science ®Google Scholar
• Golay JT, Clark EA, Beverley PCL. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985;135:3795–801
   PubMed Web of Science ®Google Scholar
• Bofill M, Janossy G, Janossa M. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985;134:1531–8
   PubMed Web of Science ®Google Scholar
• Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66–75
   PubMed Web of Science ®Google Scholar
• Allen TM, Sapra P, Moase E, et al. Adventures in targeting. J Liposome Res 2002;12:5–12
   PubMed Web of Science ®Google Scholar
• Allen TM. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 1998;56:747–56
   PubMed Web of Science ®Google Scholar
• Lothstein L, Rodrigues PJ, Sweatman TW, Israel M. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anti-Cancer Drugs 1998;9:58–66
   PubMed Web of Science ®Google Scholar
• Lothstein L, Israel M, Sweatman TW. Anthracycline drug targeting: cytoplasmic versus nuclear – A fork in the road. Drug Resis Updates 2001;4:169–77
   PubMed Web of Science ®Google Scholar
• Lothstein L, Savranskaya L, Barrett CM, et al. N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C-δ holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx. Anti-Cancer Drugs 2006;17:495–502
   PubMed Web of Science ®Google Scholar
• Ganapathi R, Grabowski D, Sweatman TW, et al. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo. Br J Cancer 1989;60:819–26
   PubMed Web of Science ®Google Scholar
• Sugaya K, Alvarez A, Bushnev S, Avgeropoulos NG. Therapy targeting cancer stem cells. US Patent 20,110,313,229; 2011
   Google Scholar
• Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004;31:196–205
   PubMed Web of Science ®Google Scholar
• Vose JM, Colcher D, Gobar L, et al. Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin’s lymphoma. Leukemia Lymphoma 2000;38:91–101
   PubMed Web of Science ®Google Scholar
• Weissleder R, Kelly K, Sun EY, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005;23:1418–23
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting — Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835--49
   PubMed Web of Science ®Google Scholar